Tempest Therapeutics (TPST) Interest Coverage Ratio (2012 - 2025)
Tempest Therapeutics (TPST) posted Interest Coverage Ratio of 0.33 for Q3 2025, up 89.13% sequentially from 3.07 in Q2 2025, and up 98.96% YoY from 0.17 in Q3 2024.
Tempest Therapeutics (TPST) Interest Coverage Ratio (2012 - 2025) Analysis & Trends
Tempest Therapeutics has reported Interest Coverage Ratio for 14 years, with the latest figure at 0.33 in Q3 2025.
- Quarterly Interest Coverage Ratio rose 98.96% year-over-year to 0.33 in Q3 2025, while the trailing twelve-month figure through Dec 2025 was 37.27 (down 14.59% YoY) and the FY2025 annual result came in at 12.02, down 4958.74% from the prior year.
- Interest Coverage Ratio improved to 0.33 in Q3 2025 per TPST's latest filing, from 3.07 in the prior quarter.
- Over five years, Interest Coverage Ratio peaked at 0.33 in Q3 2025 and troughed at 67.93 in Q1 2025.
- A 5-year average of 23.08 and a median of 20.98 in 2023 frame the typical range for Interest Coverage Ratio.
- The sharpest annual moves came in 2021 and 2025: Interest Coverage Ratio plunged 621.35% in 2021, then soared 98.96% in 2025.
- Over 5 years, Interest Coverage Ratio stood at 21.71 in 2021, then increased by 4.74% to 20.68 in 2022, then advanced by 3.62% to 19.93 in 2023, then slumped by 213.14% to 62.41 in 2024, then soared by 99.47% to 0.33 in 2025.
- According to Business Quant data, Interest Coverage Ratio over the past three periods registered 0.33, 3.07, and 67.93 for Q3 2025, Q2 2025, and Q1 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 117.59 |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 8.18 |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 2.82 |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 76.86 |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -0.08 |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 1.42 |
| 10 | Tempest Therapeutics | 4.32 Mn | 3.52 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -271.80 |
| Sep 30, 2025 | -0.33 |
| Jun 30, 2025 | -3.07 |
| Mar 31, 2025 | -67.93 |
| Dec 31, 2024 | -62.41 |
| Sep 30, 2024 | -32.07 |
| Jun 30, 2024 | -25.76 |
| Mar 31, 2024 | -21.67 |
| Dec 31, 2023 | -19.93 |
| Sep 30, 2023 | -17.67 |
| Jun 30, 2023 | -20.98 |
| Mar 31, 2023 | -21.60 |
| Dec 31, 2022 | -20.68 |
| Sep 30, 2022 | -17.94 |
| Jun 30, 2022 | -16.74 |
| Mar 31, 2022 | -11.79 |
| Dec 31, 2021 | -21.71 |
| Sep 30, 2021 | -9.43 |
| Jun 30, 2021 | -24.58 |
| Mar 31, 2021 | -22.19 |